Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

International journal of cancer·2018
Same author

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

PloS one·2017
Same author

Opening a niche for therapy: local lymphodepletion helps the immune system to fight melanoma.

The Journal of investigative dermatology·2014
Same author

Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).

PloS one·2013
Same author

Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.

Journal of the American Academy of Dermatology·2012
Same author

Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia.

BMC cancer·2012

Related Experiment Video

Updated: Apr 8, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.8K

Universal BRAF State Detection by the Pyrosequencing®-Based U-BRAF(V⁶⁰⁰) Assay.

Alexander Skorokhod1

  • 1Department of Dermatology, Heidelberg University Hospital, Im Neuenheimer Feld 440, Heidelberg, 69120, Germany, Alexander.Skorokhod@med.uni-heidelberg.de.

Methods in Molecular Biology (Clifton, N.J.)
|June 25, 2015
PubMed
Summary

A new universal Pyrosequencing assay, U-BRAF(V600), accurately detects BRAF mutations in metastatic melanoma. This automated method identifies multiple BRAF variants, aiding in targeted therapy selection for this aggressive cancer.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.7K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Related Experiment Videos

Last Updated: Apr 8, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.8K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.7K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • Malignant melanoma is an aggressive cancer with high metastatic potential.
  • BRAF mutations are key therapeutic targets in metastatic melanoma.
  • Existing BRAF detection methods have limitations in scope and automation.

Purpose of the Study:

  • To develop and validate a universal Pyrosequencing-based assay for detecting BRAF mutations.
  • To enable automated, quantitative identification of multiple BRAF variants in melanoma samples.
  • To provide a robust diagnostic tool for assessing BRAF status in clinical cohorts.

Main Methods:

  • Development of the U-BRAF(V600) assay using Pyrosequencing technology.
  • Analysis of 75 formalin-fixed paraffin-embedded melanoma metastasis samples from 29 patients.
  • Validation of results using ultra-deep sequencing.

Main Results:

  • The U-BRAF(V600) assay identified five different BRAF mutations in a single assay.
  • All identified mutant variants were quantitatively detectable and confirmed by ultra-deep sequencing.
  • The assay can automatically identify at least 36 previously published BRAF mutations, excluding false negatives.

Conclusions:

  • The U-BRAF(V600) assay is a powerful, automated, sequencing-based diagnostic tool for BRAF mutation detection.
  • Its single-reaction format and automated analysis are suitable for large clinical cohort assessment.
  • This assay facilitates precise BRAF status identification for targeted melanoma treatment.